


MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Genesys Regional Medical Center</p> <p>2. One Genesys Parkway Grand Blanc, MI 48439</p>		<p>In accordance with letter dated October 04, 2017.</p> <p>3. License number: 21-26740-01 is amended in its entirety to read as follows:</p>	<p>4. Expiration Date: June 30, 2022</p>
<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Iodine-125 permitted by 10 CFR 35.400</p>		<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p> <p>D. Sealed Sources (Medi-Physics, Inc., Model 6711; 6733; Theragenics Corporation, Model AgX100).</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As Needed</p> <p>B. As Needed</p> <p>C. 1 curie total</p> <p>D. 1 curie total</p> <p>9. Authorized use</p> <p>A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.</p> <p>B. For use in imaging and localization studies permitted by 10 CFR 35.200.</p> <p>C. For any use permitted by 10 CFR 35.300.</p> <p>D. For any manual brachytherapy procedure permitted by 10 CFR 35.400 for which the patient can be released under the provisions of 10 CFR 35.75.</p>



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
21-26740-01

Docket or Reference Number
030-34188

Amendment No. 17

- | | | | |
|---|--|--|--|
| 6. Byproduct, source, and/or special nuclear material | 7. Chemical and/or physical form | 8. Maximum amount that licensee may possess at any one time under this license | 9. Authorized use |
| E. Palladium-103 permitted by 10 CFR 35.400 | E. Sealed Sources (Theragenics Corporation, Model TheraSeed 200) | E. 1 curie total | E. For any manual brachytherapy procedure permitted by 10 CFR 35.400 for which the patient can be released under the provisions of 10 CFR 35.75. |

CONDITIONS

10. A. Licensed material may be used or stored only at the licensee's facilities located at One Genesys Parkway, Grand Blanc, Michigan.
 B. Licensed materials in Subitem No. 6. E. may be used at the licensee's facilities located at the Genesys Hurley Cancer Institute, 302 Kensington Avenue, Flint, Michigan.
11. A. The Radiation Safety Officer (RSO) for this license is Steve Min, D.O.
 B. The Assistant Radiation Safety Officer (RSO) (brachytherapy) for this license is Ibrahim S. Abdulhay, Ph.D.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:
- | <u>Authorized User(M.D.,D.O.,etc.)</u> | <u>Material and Use</u> |
|--|---|
| Ram K. Gadam, M.D. | 10 CFR 35.100, 35.200, 35.300 and 35.400, limited to iodine-125 and palladium-103 |
| Dong-Whan Oh, M.D. | 10 CFR 35.300, limited to strontium-89, and 35.400 |
| Ahmed M. Akl, M.D. | 10 CFR 35.300 and 35.400 |

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
21-26740-01

Docket or Reference Number
030-34188

Amendment No. 17

Authorized User(M.D.,D.O.,etc.)

Michael A. Gedwill, D.O.

Steve Min, D.O.

Scott E. Cheney, M.D.

Sanjay J. Talati, M.D.

Mark Robert Ludka, M.D.

Harvey Yee, M.D.

George Ascherl, M.D.

Kristin M. Nelsen, M.D.

Sambasiva Kottamasu, M.D.

Paul G. Kocheril, M.D.

Material and Use

10 CFR 35.100 and 35.200

10 CFR 35.100, 35.200 and 35.300

10 CFR 35.100 and 35.200

10 CFR 35.100 and 35.200

10 CFR 35.100, 35.200 and 35.300


10 CFR 35.100, 35.200 and 35.300

10 CFR 35.100, 35.200 and 35.300

10 CFR 35.100 and 35.200

10 CFR 35.100, 35.200 and 35.300, limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries

10 CFR 35.400



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
21-26740-01Docket or Reference Number
030-34188

Amendment No. 17

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Letter dated December 21, 2011 (ML120050509)
 - B. Letter received January 6, 2015 (ML15006A295)
 - C. Facsimile dated June 18, 2012 (ML12471A251)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

By: Colleen Carol Casey
Colleen Carol Casey
Region 3Date: December 27, 2017